ClinicalTrials.gg
Not yet recruitingNCT07938840Updated Nov 16, 2026

Opioid-Free Total Shoulder With Suzetrigine

A Phase 4 interventional study of Suzetrigine and Shoulder Arthroplasty in Osteo Arthritis Shoulders and Avascular Necrosis of Bone, sponsored by OrthoCarolina Research Institute, Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by OrthoCarolina Research Institute, Inc. · Phase 4, Interventional, and Basic science

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Osteonecrosis with a site in United States — 18 open to participants now, 34 under way, 1 of them phase 3. Osteonecrosis · United States.

Planned enrollment
38th of 55
52 · median 106
Started
2026
with 2 others
Phase 4
6 of 106
1 open now
Primary completion
2027-12
later than 11 of 33 live
Registered
106th of 106
by date

Among the 106 studies in Osteonecrosis with a site in United States, this one is the 38th largest by planned enrollment of the 55 interventional ones that give a count, is one of 3 that started in 2026, is one of 6 in phase 4, reaches primary completion later than 11 of the 33 other live ones, and was the 106th registered.

Osteonecrosis

287 studies on the registry are indexed under Osteonecrosis; 46 are open to participants now.

Browse Osteonecrosis studies →

Open to participants now

18 of the 106 studies in Osteonecrosis with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Osteonecrosis studies recruiting now, 14 (61%) set no upper age limit and 4 (17%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Osteonecrosis with a site in United States, or all of them as a file.
02

Study summary

This prospective, randomized, unblinded, controlled noninferiority study may benefit patients by determining whether an opioid-free postoperative analgesic pathway utilizing suzetrigine can provide adequate pain control following primary anatomic or reverse total shoulder arthroplasty compared with a standard opioid-containing pathway. If effective, this strategy may reduce or eliminate routine postoperative opioid use and associated adverse effects while maintaining patient satisfaction and adequate pain control. More broadly, this study will provide prospective data regarding the effectiveness and safety of suzetrigine following total shoulder arthroplasty and may help inform future opioid-free postoperative pain management protocols.

Read the detailed description

Objective 1: To determine whether an opioid-free postoperative analgesic pathway utilizing suzetrigine provides noninferior postoperative pain control at 24 hours following primary anatomic or reverse total shoulder arthroplasty compared with a standard opioid-containing postoperative analgesic pathway.

Hypothesis 1: Postoperative pain at 24 hours among patients randomized to the opioid-free suzetrigine pathway will be noninferior to postoperative pain among patients randomized to the standard opioid-containing pathway.

Objective 2: To compare postoperative opioid consumption, requirement for rescue opioid analgesia, time to first rescue opioid, postoperative pain scores, opioid-related adverse effects, and patient satisfaction between treatment groups.

Hypothesis 2: Patients randomized to the opioid-free suzetrigine pathway will have lower cumulative postoperative opioid consumption and reduced need for rescue opioid analgesia without clinically meaningful worsening of postoperative pain, or patient satisfaction.

Objective 3: To evaluate the safety profile of suzetrigine following total shoulder arthroplasty by characterizing adverse events, medication-related adverse effects, drug-drug interactions, treatment discontinuation, emergency department visits, unplanned readmissions, and reoperations.

Hypothesis 3: Patients randomized to the opioid-free suzetrigine pathway will have lower rates of opioid-related adverse events, including sedation, respiratory depression, nausea, and constipation, compared with patients randomized to the standard opioid-containing pathway.

Objective 4: To evaluate shoulder-specific functional outcomes and determine whether preoperative patient resilience is associated with postoperative pain control, opioid requirements, rescue opioid use, and patient satisfaction.

Hypothesis 4: Shoulder-specific patient-reported outcomes will be comparable between treatment groups. Greater preoperative resilience, as measured by the CD-RISC-10, will be associated with lower postoperative pain, reduced opioid consumption, decreased need for rescue opioid analgesia, and greater satisfaction with pain control.

03

Conditions studied

  • Osteo Arthritis Shoulders
  • Avascular Necrosis of Bone

Browse trials for

Keywords

  • Opioid-Free
  • Suzetrigine
  • Total Shoulder Arthroplasty
  • Reverse Total Shoulder Arthroplasty
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years
  2. Undergoing elective primary anatomic or reverse total shoulder arthroplasty
  3. English-speaking (for patient-reported outcome assessments)

Exclusion criteria

Exclusion Criteria:

  1. Revision arthroplasty procedures
  2. Total shoulder arthroplasty performed for a fracture-related indication, including acute fractures and chronic fracture sequelae (e.g., malunion or nonunion)
  3. History of chronic opioid use (defined as daily or near-daily use for ≥90 days preoperatively)
  4. to suzetrigine:

    1. Known allergy or to suzetrigine
    2. Current use of strong inhibitors (contraindicated per FDA labeling)
    3. Current use of strong or moderate CYP3A inducers (should be avoided per FDA labeling)
    4. Severe hepatic impairment ( Class C)
    5. Severe renal impairment ( \<15 mL/min/1.73 m²)
  5. Pregnancy or breastfeeding
  6. Inability to complete patient-reported outcome measures
  7. Simultaneous bilateral arthroplasty
  8. Unable or unwilling to provide or comply with study procedures
  9. Total shoulder arthroplasty performed for an oncologic indication
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Active comparator
    Standard Opioid-Containing Pathway

    Patients randomized to the control group will receive the standardized multimodal analgesic regimen outlined in Table 1, including postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. The non-opioid components of the multimodal analgesic regimen will be identical between treatment groups.

    Drug: Suzetrigine

  • Experimental
    Opioid-Free Suzetrigine Pathway

    Patients randomized to the intervention group will receive the same standardized multimodal analgesic regimen outlined in Table 2, with suzetrigine administered in place of postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. Rescue opioid analgesia will be available for inadequate pain control according to predefined rescue criteria. Suzetrigine will be administered according to the standardized study dosing protocol, with a 100 mg oral loading dose administered preoperatively, followed by 50 mg orally every 12 hours for 14 days.

    Procedure: Shoulder Arthroplasty

Interventions

  • Patients randomized to the intervention group will receive the same standardized multimodal analgesic regimen outlined in Table 2, with suzetrigine administered in place of postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. Rescue opioid analgesia will be available for inadequate pain control according to predefined rescue criteria. Suzetrigine will be administered according to the standardized study dosing protocol, with a 100 mg oral loading dose administered preoperatively, followed by 50 mg orally every 12 hours for 14 days.

  • ProcedureShoulder Arthroplasty

    Patients randomized to the control group will receive the standardized multimodal analgesic regimen outlined in Table 1, including postoperative opioid analgesia. All patients will receive an ultrasound-guided single-shot interscalene nerve block. The non-opioid components of the multimodal analgesic regimen will be identical between treatment groups.

06

What researchers measure

Primary outcomes

  1. Pain Numeric Rating Scale (NRS)

    The primary outcome will be postoperative pain measured using an 11-point Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain) at 24 hours following surgery.

    Time frame: 24 hours post-surgery

Secondary outcomes

  1. Pain Numeric Rating Scale (NRS)

    The primary outcome will be postoperative pain measured using an 11-point Numeric Rating Scale (NRS; 0 = no pain, 10 = worst imaginable pain)

    Time frame: From enrollment to the end of treatment at 1 year

  2. Morphine Milligram Equivalents (MME)

    Cumulative opioid consumption converted to MME

    Time frame: 24 hours postoperative

  3. Morphine Milligram Equivalents (MME)

    Cumulative opioid consumption converted to MME

    Time frame: 48 hours postoperative

  4. Rescue opioid analgesia

    Requirement for rescue opioid analgesia (yes/no)

    Time frame: From enrollment to the end of treatment at 1 year

  5. Patient satisfaction with overall pain control

    Patient satisfaction with overall pain control, measured on a scale of 0-10 with 0 being less satisfied and 10 being completely satisfied.

    Time frame: From enrollment to the end of treatment at 1 year

  6. Hospital length of stay

    Time spent in hospital

    Time frame: At the time of surgery treatment.

  7. American Shoulder and Elbow Surgeons (ASES) Shoulder Score

    The American Shoulder and Elbow Surgeons Shoulder Score (ASES) was designed to assess the condition of the shoulder, regardless of disease pathology. The ASES is a composite instrument, requiring both a physician assessment and a patient-completed portion; however, it is commonly presented as solely the patient-reported survey. This includes a section on pain (7 items) and a section on activities of daily living (10 items). Scores range from 0 to 100 with a score of 0 indicating a worse shoulder condition and 100 indicating a better shoulder condition.

    Time frame: From enrollment to the end of treatment at 1 year

  8. Single Assessment Numeric Evaluation (SANE)

    Patients are asked: "How would you rate your shoulder today as a percentage of normal (0% to 100% scale, with 100% being a completely normal shoulder)?"

    Time frame: From enrollment to the end of treatment at 1 year

  9. Simple Shoulder Test (SST)

    Self-reported questionnaire that evaluates shoulder function, comfort, and strength through simple "yes" or "no" questions that result in 0% (worst function) to 100% (best function) score.

    Time frame: From enrollment to the end of treatment at 1 year

07

Study locations

1 site
08

References and documents

Publications

  • Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30. PubMed 18929686 ↗
  • Klein B, Faridi A, von Tempelhoff GF, Heilmann L, Mittermayer C, Rath W. A whole blood flow cytometric determination of platelet activation by unfractionated and low molecular weight heparin in vitro. Thromb Res. 2002 Dec 15;108(5-6):291-6. doi: 10.1016/s0049-3848(03)00094-x. PubMed 12676188 ↗
  • Bertoch T, D'Aunno D, McCoun J, Solanki D, Taber L, Urban J, Oswald J, Swisher MW, Tian S, Miao X, Correll DJ, Negulescu P, Bozic C, Weiner SG. Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials. Anesthesiology. 2025 Jun 1;142(6):1085-1099. doi: 10.1097/ALN.0000000000005460. Epub 2025 Mar 21. PubMed 40117446 ↗
  • Dib-Hajj SD, Yang Y, Black JA, Waxman SG. The Na(V)1.7 sodium channel: from molecule to man. Nat Rev Neurosci. 2013 Jan;14(1):49-62. doi: 10.1038/nrn3404. Epub 2012 Dec 12. PubMed 23232607 ↗
  • Zakrzewska JM, Palmer J, Morisset V, Giblin GM, Obermann M, Ettlin DA, Cruccu G, Bendtsen L, Estacion M, Derjean D, Waxman SG, Layton G, Gunn K, Tate S; study investigators. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. Lancet Neurol. 2017 Apr;16(4):291-300. doi: 10.1016/S1474-4422(17)30005-4. Epub 2017 Feb 17. PubMed 28216232 ↗
  • Vadivelu N, Kai AM, Kodumudi V, Sramcik J, Kaye AD. The Opioid Crisis: a Comprehensive Overview. Curr Pain Headache Rep. 2018 Feb 23;22(3):16. doi: 10.1007/s11916-018-0670-z. PubMed 29476358 ↗
  • Kessler ER, Shah M, Gruschkus SK, Raju A. Cost and quality implications of opioid-based postsurgical pain control using administrative claims data from a large health system: opioid-related adverse events and their impact on clinical and economic outcomes. Pharmacotherapy. 2013 Apr;33(4):383-91. doi: 10.1002/phar.1223. PubMed 23553809 ↗
  • American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2012 Feb;116(2):248-73. doi: 10.1097/ALN.0b013e31823c1030. No abstract available. PubMed 22227789 ↗
  • Wylde V, Beswick A, Bruce J, Blom A, Howells N, Gooberman-Hill R. Chronic pain after total knee arthroplasty. EFORT Open Rev. 2018 Aug 16;3(8):461-470. doi: 10.1302/2058-5241.3.180004. eCollection 2018 Aug. PubMed 30237904 ↗
  • Sloan M, Premkumar A, Sheth NP. Projected Volume of Primary Total Joint Arthroplasty in the U.S., 2014 to 2030. J Bone Joint Surg Am. 2018 Sep 5;100(17):1455-1460. doi: 10.2106/JBJS.17.01617. PubMed 30180053 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938840
Lead sponsor
OrthoCarolina Research Institute, Inc.
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Caleb J Michalek, BS
Contact
caleb.michalek@orthocarolina.com
704-323-3698
Caleb Lifsey
Contact
caleb.lifsey@orthocarolina.com
704-323-2412
Nady Hamid, MD
principal investigator · OrthoCarolina Research Institute, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion